1	Running Title: NLP-RNAseq in AD
2	
3	
4	Association of RDoC dimensions with post-mortem brain transcriptional profiles
5	in Alzheimer's Disease
6	
7	Weiqian Jiang <sup>1, *</sup> , Jonathan Vogelgsang <sup>1, *</sup> , Shu Dan <sup>1</sup> , Peter Durning <sup>1</sup> , Thomas H. McCoy <sup>2</sup> ,
8	Sabina Berretta <sup>1, *</sup> , and Torsten Klengel <sup>1, *</sup>
9	
10	<sup>1</sup> Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
11	<sup>2</sup> Center for Quantitative Health, Massachusetts General Hospital, Harvard Medical School, Boston, MA
12	02114, USA
13	* Denotes equal contribution
14	
15	
16	
17	Correspondence: Sabina Berretta MD, McLean Hospital, 115 Mill Street, Belmont MA 02478
18	(sberretta@mclean.harvard.edu) and Torsten Klengel MD, PhD, McLean Hospital, 115 Mill Street,
19	Belmont MA 02478 ( <u>tklengel@mclean.harvard.edu</u> )
20	
21	
22	
23	
24	Acknowledgment statement: This work was supported by P50MH115874, R01MH120991, German
25	Research Foundation #413501650, P50NM119467, Alzheimer's Association #AACSFD-23-1149842, Eric
26	Dorris Memorial Fellowship, Rappaport Mental Health Research Award, R01HD102974, and
27	R01AG070704.
28	
29	Author contributions: WJ, JSV, TK and SB designed the study. WJ, JSV, SD, and PD performed analyses.
30	WJ, JSV, TK and SB wrote the manuscript. All authors approved the final version of the manuscript.
31	
32	<b>Competing interests:</b> The authors have no conflict of interest to disclose.

## 33 Abstract

34

- 35 INTRODUCTION: Neuropsychiatric symptoms are common in people with Alzheimer's disease (AD)
- 36 across all severity stages. Their heterogeneous presentation and variable temporal association with
- 37 cognitive decline suggest shared and distinct biological mechanisms. We hypothesized that specific
- 38 patterns of gene expression associate with distinct NIMH Research Domain Criteria (RDoC) domains in

39 AD.

- 40 METHODS: Post-mortem bulk RNAseq on the insula and anterior cingulate cortex from 60 brain donors
- 41 representing the spectrum of canonical AD neuropathology combined with natural language processing
- 42 approaches based on the RDoC Clinical Domains.
- 43 RESULTS: Distinct sets of >100 genes (p<sub>FDR</sub><0.05) were specifically associated with at least one clinical
- 44 domain (Cognitive, Social, Negative, Positive, Arousal). In addition, dysregulation of immune response
- 45 pathways was shared across domains and brain regions.
- 46 DISCUSSION: Our findings provide evidence for distinct transcriptional profiles associated with RDoC
- 47 domains suggesting that each dimension is characterized by specific sets of genes providing insight into
- 48 the underlying mechanisms.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- -
- 64

## 65 Introduction

66

67 Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia. While 68 advanced stages of AD are characterized by severe cognitive impairment, varying degrees of 69 neuropsychiatric symptoms (NPS) including depression, agitation, aggression, and apathy can be present 70 across the entire spectrum of AD<sup>1,2</sup>. NPS can lead to accelerated disease progression, increased caregiver 71 burden, and earlier death. Treatment of these symptoms with medications used for non-72 neurodegenerative psychiatric disorders is based on the largely unchallenged assumption that their 73 biological underpinnings are equivalent. The clinical diagnosis of AD is based on a combination of clinical 74 and pathological measurements, either biomarkers in cerebrospinal fluid (CSF) or PET imaging of 75 Amyloid-β or TAU deposition. Neuropathologically, AD is characterized by extracellular plaques of 76 misfolded  $\beta$ -amyloid (A $\beta$ ) aggregates and intracellular neurofibrillary tangles (NFT) formed by paired 77 helical filaments of hyperphosphorylated tau protein<sup>3</sup>. While deposition of A $\beta$  and NFT are considered 78 neuropathological hallmarks of AD<sup>4</sup>, studies on transcriptional changes in AD using post-mortem brain 79 tissue suggest the dysregulation of multiple cellular pathways including synaptic dysfunction, gliosis, demyelination, and inflammation leading to neuronal loss<sup>5-9</sup>. Bridging between canonical and molecular 80 81 changes on one side and symptoms on the other is particularly challenging, even more so in the context 82 of clinical, genetic, and neuropathological heterogeneity among persons with AD<sup>10</sup>. 83

84 Most large-scale transcriptional studies focus on extensively studied brain regions such as hippocampus, anterior cingulate cortex (BA32/BA33) and prefrontal cortex (BA9, BA10, BA46)<sup>6-9,11,12</sup>. In contrast, the 85 86 insula, which is located deep within the lateral sulcus that separates the temporal from the parietal and 87 frontal lobes, remains largely understudied. It has been traditionally viewed as a paralimbic or limbic integration cortex integrating visceral information<sup>13,14</sup>. Recently, imaging studies have sparked 88 89 considerable interest in investigating the role of the insular cortex in the context of emotion, pain, 90 decision making, motor control, and social functions<sup>15</sup>. The insular cortex is connected to a wide variety 91 of brain regions including the frontal, anterior cingulate and parietal cortex, limbic areas such as the 92 amygdala, hypothalamus, and entorhinal cortex, and to sensorimotor brain regions<sup>16,17</sup>. The central role 93 of the insular cortex in relevant circuits is supported by several neuroimaging studies suggesting its 94 involvement in AD and AD-related NPS<sup>18-21</sup>. However, transcriptomic studies investigating molecular 95 mechanisms underlying pathological alterations of the insular cortex in AD remain scarce.

96

97 To date, most transcriptomic studies focus on the comparison between normative individuals and people 98 with either early- or late-onset AD<sup>5,8,12</sup>. Single-nucleus RNAseq studies have provided significant insight 99 into AD pathology by revealing distinct gene expression patterns in multiple cell types<sup>22,23</sup>. Although very 100 informative, categorical diagnosis comparison designs may not be well suited to account for 101 interindividual heterogeneity in symptom presentation, particularly regarding comorbid NPS. To 102 overcome these limitations, we previously applied a natural language processing (NLP) algorithm to post-103 mortem medical records of donors with and without AD to provide dimensional phenotyping within the 104 context of the NIMH Research Domain Criteria (RDoC)<sup>24</sup>. RDoC is a multidimensional framework 105 composed of different neuropsychiatric domains capturing a spectrum of symptoms rooted in brain 106 circuits and biology $^{25-27}$ . 107 108 In this study, we performed an RNAseg analysis in the anterior Insula (aINS; BA16) and dorsal anterior 109 cingulate cortex (dACG; BA32), focusing on a dimensional approach based on the NIMH RDoC domain 110 matrix including Negative Valence Systems, Positive Valence Systems, Cognitive Systems, Social

111 Processes, and Arousal and Regulatory Systems. Using a generalized linear regression model, we show

112 that transcriptomic changes associated with dimensional RDoC clinical domain scores provide a deeper

and more nuanced insight into the underlying molecular correlates of dimensional symptoms

- 114 presentation in AD. Importantly, our results suggest common and distinct molecular mechanisms across
- 115 RDoC domains and brain regions.
- 116
- 117 Methods
- 118
- 119 Experimental Subjects and Tissue Preparation

120 All tissue samples and medical records were obtained from the Harvard Brain Tissue Resource Center

121 (HBTRC; operating under the MGB McLean Institutional Review Board (IRB)). The subject cohort (n=60)

available for this study included brain donors representing the full spectrum of Braak & Braak

- neuropathological stages, thus representing the neuropathological AD progression from Braak and Braak
- stages 0 to II (unaffected controls) to Braak and Braak stages III and IV (mild to moderate AD pathology)
- 125 and Braak and Braak stages V and VI (severe AD pathology)<sup>28</sup>. Only donors with sufficient medical
- 126 records and a life diagnosis by a qualified clinician were included. Donors with significant psychiatric

127 conditions diagnosed during adolescence, early- or mid-adulthood were not included. Similarly, we
 128 excluded donors with non-AD neurological diagnoses.

129 Medical records in hard copies were scanned into computer-readable text files using optical character

130 recognition. Text files were processed using RDoC-based NLP algorithms to obtain quantitative

131 measures of clinical domain scores, as described by McCoy et al<sup>24</sup> (<u>https://qithub.com/thmccoy/CQH-</u>

132 *Dimensional-Phenotyper*). Access to donors' medical records and other sensitive data was restricted to

133 IRB-authorized investigators; all other investigators contributing to this study were given access to de-

identified data, according to the Health Insurance Portability and Accountability Act (HIPAA) regulations.

135 Detailed metadata information for each sample is given in **Supplementary Data 1.** A summary of the

136 cohort subject basic data by RNA-seq batch is included in **Supplementary Data 2** and individual scores in

each domain is given in **Supplementary Data 3**.

138 The dACG (BA32) and the aINS (BA16) were isolated from flash-frozen human post-mortem brain tissue

samples. Tissue blocks were sectioned using a cryostat and 5 x 40µm sections (approximately 20 mg)

140 were collected for RNA extraction using Absolutely RNA Miniprep Kit (Agilent, Lexington, MA) according

to the manufacturer's protocol. Briefly, 400μl lysis buffer, including 2.8μl β-mercaptoethanol were

added to the tissue and homogenized. 400µl 70% ethanol was added to the tissue homogenate and

vortexed for 5 seconds. 400µl homogenate was transferred to an RNA Binding Spin Cup and centrifuges

for 60 seconds at 16,000 x g and repeated once. The column was washed once with 600µl Low-Salt

145 Wash Buffer and centrifuged at max speed to dry, followed by a 15-minute DNase I digestion at room

temperature. Next, the column was washed with 600µl High-Salt Wash Buffer, 600µl Low-Salt Wash

147 Buffer, and 300µl Low-Salt Wash Buffer, each step followed by 60 seconds centrifugation at max. speed.

148 Lastly, 40µl Elution Buffer was added on the matrix and incubated for 120 seconds followed by

149 centrifugation at maximum speed for 60 seconds.

# 150 RNA-Seq library preparation and sequencing

151 RNA library preparation and sequencing were conducted at Azenta Life Sciences (South Plainfield, NJ,

152 USA). Briefly, RNA samples were quantified using Qubit 2.0 Fluorometer (ThermoFisher Scientific,

153 Waltham, MA, USA) and RNA integrity was checked with 4200 TapeStation (Agilent Technologies, Palo

154 Alto, CA, USA). RNA samples were treated with TURBO DNase (Thermo Fisher Scientific, Waltham, MA,

155 USA) to remove DNA following manufacturer's protocol. rRNA depletion sequencing libraries were

156 prepared by using QIAGEN Fastselect HMR. RNA sequencing library preparation uses NEBNext Ultra II 157 RNA Library Preparation Kit for Illumina by following the manufacturer's recommendations (NEB, 158 Ipswich, MA, USA). Briefly, enriched RNAs were fragmented for 15 minutes at 94 °C. First strand and 159 second strand cDNA were subsequently synthesized. cDNA fragments were end repaired and adenylated 160 at 3'ends, and universal adapters are ligated to cDNA fragments, followed by index addition and library 161 enrichment with limited cycle PCR. Sequencing libraries were validated using the Agilent Tapestation 162 4200 (Agilent Technologies, Palo Alto, CA, USA), and quantified using Qubit 2.0 Fluorometer 163 (ThermoFisher Scientific, Waltham, MA, USA) as well as by quantitative PCR (KAPA Biosystems, 164 Wilmington, MA, USA). Sequencing libraries were multiplexed and clustered onto a flow-cell. After 165 clustering, the flow-cell was loaded onto the Illumina Novaseq instrument according to manufacturer's 166 instructions. The samples were sequenced using a 2x150bp Paired End (PE) configuration. Image analysis 167 and base calling were conducted by the Control Software. Raw sequence data (.bcl files) generated from 168 Illumina was converted into fastq files and de-multiplexed using Illumina bcl2fastq 2.20 software. One 169 mismatch was allowed for index sequence identification.

170

## 171 Processing of RNA-seq data

172 RNA-seq data was processed and analyzed using the bcbio-nextgen Bulk RNA-seq pipeline (available at 173 https://github.com/bcbio/bcbio-nextgen). Paired-end sequence reads were aligned to human genome UCSC GRCh38.p14 using STAR<sup>29</sup>. Quality metrics were assessed using Samtools<sup>30</sup>, with an average 174 175 mapping rate of 84%. No samples were excluded based on sequencing QC metrics. Transcript counts 176 from aligned reads were quantified using Salmon<sup>31</sup>, then summarized to the gene level using the R 177 package Tximport<sup>32</sup>. Sequencing depth was normalized between samples using the median of ratios 178 method in R package DESeq2<sup>33</sup>. Low expressed genes with less than 10 reads in over half of the total 179 sample were removed.

#### 180 Differential Expression Analysis over Clinical Domain Scores

Scores for RDoC-based clinical domains were derived using NLP algorithms as previously described in
 Vogelgsang et al.<sup>34</sup> The clinical domain scores of all donors were binned between 0 and 1, in 0.1 intervals
 and considered on a dimensional scale from 0 (lower limit) to 1 (upper limit) (Supplementary Data 3).
 Note that higher scores indicate more severe symptoms (e.g. more severe cognitive impairment); thus, a
 positive correlation between gene expression and clinical domain scores indicates that higher gene

expression is associated with greater symptom severity. Differential gene expression analyses in the aINS
 and dACG for over dimensional scores for each of the 5 clinical domains using the filtered gene set was
 performed by ImpulseDE2<sup>35</sup>.

189

190 Briefly, after filtering, normalized counts were used in a principal component analysis (PCA) to identify 191 potential covariates. The first five PCs were correlated with known technical and biological variables, 192 resulting in significant correlations for neuropathological Braak & Braak stage, brain region, sex, age, RIN, 193 and sequencing batch, but not PMI (Supplementary Figure 1). To further explore residual unknown 194 sources of variation including the influence of changing cell type composition, medication, and comorbidities, surrogate variable analysis (SVA)<sup>36</sup> was used, which yielded two significant SVs correlated 195 196 with the first five PCs. Given the overall influence of Braak & Braak stages, brain regions, sex, age, RIN, 197 sequencing batch, SV1, and SV2 on the data, we further explored the relevance of covariates across the 198 RDoC cognition domain for each brain region and found that sex, sequencing batch and Braak & Braak 199 status showed significant associations, while age, RIN, PMI, SV1, and SV2 were not significantly 200 associated across the dimension (Supplementary Data 1). Thus, the final model to identify genes 201 progressively regulated along the axis from low to high clinical domain scores in ImpulseDE2 included sex 202 and sequencing batch as covariates. Braak and Braak stage was not included due to collinearity with the 203 clinical domain scores. Statistical significance of differential expression was defined at p<sub>FDR</sub><0.05.

204

## 205 Functional Enrichment Analysis

A one-tailed hypergeometric test was conducted for pathway enrichment analysis using Metascape<sup>37</sup>.

207 We included multiple databases such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and

208 Genomes (KEGG), Reactome and Wikipathway, separately for up- and downregulated differentially

- 209 expressed (DE) genes from the dimensional analyses. Statistical significance was defined at  $p_{FDR} < 0.05$ .
- 210

# 211 Data Availability

RNAseq data is available through the GEO accession number GSE261050. The code of the analyses is
 available at the Klengel Lab GitHub page under https://github.com/klengellab/RDoC\_RNAseq.

- 214
- 215
- 216

~ - -

• •

\_

217	Results		
218			
219	Differential Gene Expression in aINS and dACG as a Function of Dimensional Cognition Scores		
220			
221	In a previous proof-of-concept work, we used NLP algorithms to obtain cognition scores and showed that		
222	they are significantly associated with neuritic plaque load across all lobes of the brain <sup>38</sup> . The correlation		
223	of this classical neuropathological hallmark of AD with compelling evidence for a direct relationship to		
224	cognition <sup>28,39,40</sup> and cognition scores provided evidence for the feasibility and validity of post-mortem		
225	dimensional phenotyping of brain donor electronic health records beyond categorical diagnoses,		
226	allowing for a more granular investigation of neuropsychiatric symptoms in AD.		
227			
228	Because the donor cohort available for this study only partially overlaps with the prior one <sup>38</sup> , we again		
229	tested the association between neuritic plaque load and cognitive symptom burden. As expected, the		
230	cohort analyzed here showed a significant association between neuritic plaque load across all lobes and		
231	cognition scores, as well as a significant association of Braak & Braak stages with cognition scores		
232	(Supplementary Data 4).		
233			
234	To investigate the underlying molecular changes associated with dimensional cognition burden, we		
235	regressed cognition scores over gene expression in the dACG and aINS of all donors, representing the full		
236	spectrum of Braak & Braak stages (from 0 to VI) using ImpulseDE2 <sup>35</sup> . In the aINS, 109 DEGs at $p_{FDR}$ <0.05		
237	showed a monotonous increase or decrease of expression across cognition score (Figure 1 A,		
238	Supplementary Data 5). Out of these 109 genes, 67 genes were positively correlated with more severe		
239	cognitive impairment. Top hits included genes involved in innate immune response, such as CD177 and		
240	HSPA6. The remaining 42 genes were negatively correlated with cognition scores. These included		
241	PNMA6B, a member of paraneoplastic Ma antigen (PNMA) family, which is associated with immune-		
242	related diseases and neurological disorders <sup>41,42</sup> , alongside a large number of non-coding RNAs (ncRNAs)		
243	and pseudogenes.		
244			
245	In dACG, 107 DEGs (p <sub>FDR</sub> <0.05) showed a monotonous increased or decreased expression in association		
246	with cognition scores (Figure 1 B, Supplementary Data 5). Among the 48 genes with increased		
247	expression associated with more severe cognition scores. LAD1 and MMP23A were the top hits, with a		

strong positive correlation with cognitive impairment. Similar to the aINS, top downregulated DEGs

primarily belong to the less known group of pseudogenes or ncRNAs, with a total of 59 genes showingsignificant negative correlation with cognition severity.

## 251 Differential Gene Expression in aINS and dACG as a Function of Clinical Domain Scores

252 Next, we focused on the Arousal Regulatory, Negative Valence, Positive Valence, and Social Systems 253 domain scores. As expected, all domains were highly intercorrelated (Pearson  $r=0.88 \pm 0.04$ ). As shown 254 in Figure 2 A and Supplementary Data 5, each clinical domain was associated with distinct sets of DEGs 255 (all p<sub>FDR</sub><0.05). In the aINS, DEGs were detected in association with Arousal (56 genes increased; 45 256 genes decreased), Negative valence (40 genes increased; 56 decreased), Positive valence (61 genes 257 increased; 61 genes decreased) and Social domain (61 genes increased; 49 genes decreased). Similar 258 number of DEGs were detected in dACG in association with Arousal (42 genes increased; 52 genes 259 decreased), Negative valence (65 genes increased; 60 genes decreased), Positive valence (46 increased; 260 55 genes decreased) and Social domain (55 genes increased and 65 genes decreased (Figure 2 B and 261 Supplementary Data 5). Notably, the majority of DEGs in aINS and dACG were uniquely associated with 262 one domain with moderate to minimal overlap between domains (Figure 2 C and D Supplementary Data 263 5 and 6).

#### 264 Pathway Enrichment in aINS and dACG as a Function of Clinical Domain Scores

265 Next, we assessed functional pathways across all clinical domains in aINS and dACG. Across both brain 266 regions and all clinical domains, we found a predominating enrichment of pathways related to immune 267 system functions. Enrichment analyses in the aINS revealed multiple pathways associated with innate 268 immune responses shared across the five domains (Figure 2 E, Supplementary Data 7), including 269 neutrophil degranulation, LPS response and leukocyte migration, supporting the notion that immune 270 dysregulation is a driving factor for AD disease progression across all clinical domains investigated. In 271 contrast to the broad association of innate immune response pathways with all clinical domains, other 272 functional pathways were unique to a specific domain or a subset of domains. Specifically, pathways 273 associated with the cognition domain included those involved in learning and memory, microtubule-274 based movement, circadian rhythm, and response to TGF-β. Moreover, pathways related to sex 275 hormones were unique to the arousal, cognition, and negative domain. As an example, FSHB, beta 276 subunit of follicle-stimulating hormone was specifically increased in domain arousal and cognition. This 277 hormone, crucial in the female reproductive cycle as well as in stimulating production and maturation of

sperm in males, has been shown to accelerate amyloid-β and Tau deposition in neurons and to impair
cognition in an AD rodent model<sup>43</sup>, and sex steroid hormones have been associated with AD onset as
well as progression<sup>44</sup>. Very similar shared biological processes were detected among the five domains in
BA32 (Figure 2 F, Supplementary Data 7). Unique pathways included complement activation shared by
domain arousal, cognition and social, which has been associated with Aβ clearance<sup>45</sup>.

283

# 284 Discussion

285

Historically, investigations on AD placed emphasis on the pathogenesis of canonical findings such as
 neurofibrillary tangles and senile plaques. Although the relevance of β-amyloid and tau proteinopathies
 is uncontroversial, growing evidence supports the contribution of additional molecular pathways such as
 immune regulation, oxidative stress, insulin signaling and lipid metabolism, synaptic regulation and sex
 hormone signaling<sup>46,47</sup>.

291

292 The relationship between AD neuropathology and dysregulation of molecular pathways on the one hand 293 and AD symptomatology on the other hand has been predominantly investigated in the context of 294 categorical diagnosis frameworks and with strong emphasis on cognitive impairment. However, 295 categorical diagnoses have been criticized for their limitations and their potential to impede scientific 296 progress<sup>48</sup>. Over the last decade, efforts have been made to overcome these limitations by establishing 297 dimensional models of human cognition, behavior and emotions that are based on neurobiological or 298 behavioral phenotypes such as RDoC or HiTOP<sup>49,50</sup>. Although these efforts are not without controversy, 299 dimensional phenotyping across diagnostic entities is a promising approach to identify molecular 300 mechanisms behind distinct symptoms and syndromes. Distinct neuropathological and molecular 301 patterns may, at least in part, account for the heterogenous clinical presentation of neuropsychiatric 302 disorders including AD<sup>51</sup>.

303

We previously investigated the relationship between continuous cognitive symptom dimension in AD and classical neuropathological changes. Our results confirmed an association of NLP-derived cognitive scores with hallmark neuropathological findings and provided a proof-of-concept supporting the validity of NLP-based methodologies to obtain quantitative measures of functional RDoC domains from postmortem health records. Here we link dimensional clinical domain scores to bulk RNAseq data on 101 309 post-mortem brain samples from aINS and dACG to test the hypothesis that gene expression signatures 310 are associated with dimensional phenotype constructs derived from post-mortem brain donor health 311 records. Our results provide evidence for gene expression signatures that define each clinical domain 312 and brain region, potentially facilitating future research into more granular phenotypes beyond 313 categorical diagnoses. Our data also suggest immune-related transcriptional changes as a common 314 underlying mechanism across all domains and brain regions. 315

Results of linear regression models across all clinical domains in both brain regions yielded between n=94 and n=125 DEGs associated with one of the domains (Supplemental Data 5). Comparisons of upor downregulated DEGs showed only a moderate level of overlap between clinical domains, suggesting that each domain may be defined by a specific set of differentially expressed genes (Figure 2 C and D). Notably, immune response pathways were robustly dysregulated across all clinical domains. These findings contribute to growing evidence for a critical role of immune signaling factors in AD and suggest their pervasive contribution to the overall clinical presentation of this disorder.

323

324 We detected a substantial number of FDR-significant DEGs with an increasing or decreasing expression 325 pattern over cognition scores in aINS (n=109 DEGs) and dACG (n=107 DEGs) (Figure 1 A and B). In the 326 aINS, a subset of genes was uniquely differentially expressed in association with the cognitive domain 327 (upregulated n=26, downregulated n=16, Figure 2 C, Supplementary Data 7) including H2AC7 and LCN2 328 (both upregulated). H2AC7, a H2A histone protein variant, is involved in regulating cell cycle processes. 329 Interestingly, reactivation of cell cycle related genes and DNA double-strand breaks are early pathological 330 hallmarks of AD, and eventually lead to neuronal loss<sup>52,53</sup>. LCN2 is involved in a wide range of biological 331 processes such as regulation of iron homeostasis, inflammation, cell death, survival, differentiation and 332 migration<sup>54</sup>. LCN2 in the brain has been implicated in cognition and behavior while increased levels of 333 LCN2 are associated with age-related CNS diseases such as AD and PD<sup>55</sup>. In the dACG, a total of 38 genes 334 were uniquely differentially expressed with the cognitive domain (upregulated n=19, downregulated 335 n=19, Figure 2 D, Supplementary Data 7). Top hits include LAD1 and MMP23A which showed a strong 336 positive correlation with cognition scores. LAD1 is involved in cell anchoring and adhesion and MMP23A 337 is one of the matrix metalloproteinase (MMP) family engaged in cell adhesion and matrix degradation in 338 the extracellular matrix (ECM), enhancing immune cells migration and inflammatory response<sup>56</sup>. 339

340 DEGs that are uniquely up- or down-regulated over specific clinical domains may shed light on 341 underlying molecular mechanisms of NPS in AD. For example, PINX1 and HSPA7 showed a unique 342 signature of increased expression over the arousal domain in the aINS. PINX1 can inhibit the activity of 343 telomerase, which is protective against ROS production and oxidative stress at different stages of AD pathology<sup>57</sup>. Interestingly, telomerase activity is also associated with circadian oscillation under the 344 345 control of CLOCK-BMAL1 heterodimers<sup>58</sup>, a molecular mechanism fundamental to the arousal domain. 346 HSPA7 is a member of the human Hsp70 family and overexpression of Hsp70 can have protective effects 347 on neurons in AD<sup>59</sup>. AMIGO3 is among genes uniquely associated with the positive domain in the aINS. 348 AMIGO3 triggers the inhibition of oligodendrocyte precursor cell maturation, myelin production and 349 neurite outgrowth<sup>60</sup>. Similar, we found NPAS4 showing a unique positive association with the positive 350 domain in the aINS. NPAS4 encodes a transcription factor that regulates a number of downstream genes 351 such as BDNF, NARP and KCNA1, which mediate diverse effects of synaptic modulation and experience-352 dependent memory formation<sup>61</sup>. Two other genes uniquely upregulated in association with the social 353 domain in the aINS are NME8 and E2F8. NME8, encoding TXNDC3 is involved in cytoskeletal function and axonal transport and identified as late-onset AD risk gene from GWAS and meta-analysis<sup>62</sup>. E2F8 is a 354 355 member of E2F transcription factor family that regulate the transition from G1 to S phase, and aberrant 356 activation of neuronal cell cycle has also been postulated as a mechanism of neuronal loss in AD<sup>63</sup>. Lastly, 357 IL6, a major inflammatory marker, showed an increasing expression pattern in association with the 358 negative domain in the aINS. This is consistent with previous meta-analyses showing positive association 359 between inflammatory markers and depression<sup>64</sup>.

360

361 Several FDR-significant up- and downregulated genes were uniquely associated with individual clinical 362 domains in the dACG. For example, CNTF, encoding a neurotrophic factor involved in neurotransmitter 363 synthesis and neurite outgrowth, was uniquely upregulated in the social domain. PINX1 was upregulated 364 across the positive domain but downregulated across the cognitive and negative domain in the dACG. 365 Interestingly it shows a unique upregulation with arousal in BA16 (see above). SLC5A1, encoding the 366 sodium/glucose cotransporter SGLT1 and LCN2, encoding a glycoprotein expressed in reactive microglia 367 and astrocytes in AD, were uniquely associated with the positive domain our cohort<sup>65</sup>. Genes associated 368 with the negative domain and prior evidence for a role in AD included IL1RL1, LIF, and FGB<sup>66-68</sup>. 369

Although the number of overlapping DEGs across clinical domains was small (Figure 2 C and D), these
 genes could point to molecular mechanisms that influence a broader set of symptoms in AD. Common

372 upregulated genes across all domains (including the cognitive domain) in the aINS indicate the overall 373 activation of processes related to immune activation, which is an important mechanism contributing to 374 AD pathogenesis and progression. For example, we found CXCL10, a chemokine that can mediate 375 immune activation by binding to its receptor CXCR3 and activate and recruit leukocytes<sup>69</sup>. We also found *MUC13*, which promotes NF-kB activity and leads to increased production of IL-8<sup>70</sup>. On the other hand, 376 377 as a subtype of mucins, mature MUC13 can provide numerous glycosylation sites with its N-terminus 378 located on the cell surface, and N-linked glycosylation has been recently reported to affect the 379 progression of  $AD^{71}$ . In total, we detect n=70 genes upregulated at  $p_{FDR} < 0.05$  across at least two domains. 380 In contrast, n=70 downregulated genes at p<sub>FDR</sub><0.05 are shared across at least two domains 381 (Supplementary Data 6).

382

383 In the dACG, several genes including USP17L11, USP17L17, USP17L26, and USP17L28 were upregulated 384 across different clinical domains. They belong to the deubiquitinating enzyme (DUB) family of genes and 385 are involved in regulating the removal of ubiquitin molecules from proteins<sup>72</sup>. The ubiquitin-proteasome 386 system (UPS) maintains mitochondrial homeostasis by regulating mitochondrial proteome and 387 mitophagy<sup>73</sup>. UPS impairment and mitochondrial dysfunction have been implicated as hallmarks of aging 388 and associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson disease<sup>74,75</sup>. 389 Notably, MT-RNR2, encoding the polypeptide Humanin, is also upregulated across the cognitive, arousal, and social domain in the dACG<sup>76</sup>. In total, we detect n=66 genes upregulated at pFDR<0.05 across at least 390 391 two domains. In contrast, n=78 downregulated genes at pFDR<0.05 are shared across at least two 392 domains (Supplementary Data 6).

393 At the level of regulatory pathways, we found a more congruent profile with shared pathways related to

the innate immune response defining upregulated gene profiles, and GTPase activity defining

395 downregulated gene profiles across domains and (Figure 2 E and F, Supplemental Data 7). This

396 contrasting result compared to the regulation of individual genes may reflect the overall strong impact of

immune dysregulation, vesicle trafficking, and cell cycle regulation in AD progression.

398

399 In summary, the use of NLP-derived dimensional phenotypes may provide more specific insight into the

400 underlying biology of AD. Each clinical domain score was associated with a distinct pattern of DEGs with

401 a limited number of DEGs shared across domains. However, changes across clinical domains may be

402 driven by shared functional pathways with a focus on immune system dysregulation.

Sabates, J. et al. The Associations Between Neuropsychiatric Symptoms and Cognition in People

with Dementia: A Systematic Review and Meta-Analysis. Neuropsychology Review 34, 581-597,

## 403 References

1

404

405

406

- 407 doi:10.1007/s11065-023-09608-0 (2024). 408 2 Zhao, Q. F. et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: 409 Systematic review and meta-analysis. J Affect Disord 190, 264-271, 410 doi:10.1016/j.jad.2015.09.069 (2016). 411 3 Braak, H., Ra, d. V., En, J. S., Bratzke, H. & Braak, E. v. J. P. i. b. r. Neuropathological hallmarks of 412 Alzheimer's and Parkinson's diseases. 117, 267-285 (1998). 413 4 Strooper, B. D. & Karran, E. J. C. The Cellular Phase of Alzheimer's Disease. 164, 603-615 (2016). 414 5 Colangelo, V. et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: 415 transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-416 inflammatory signaling. 70, 462-473 (2002). 417 6 Zhang, B. et al. Integrated systems approach identifies genetic nodes and networks in late-onset 418 Alzheimer's disease. 153, 707-720 (2013). 419 7 Miller, J. A., Woltjer, R. L., Goodenbour, J. M., Horvath, S. & Geschwind, D. H. J. G. m. Genes and pathways underlying regional and cell type changes in Alzheimer's disease. 5, 1-17 (2013). 420 421 8 Bossers, K. et al. Concerted changes in transcripts in the prefrontal cortex precede 422 neuropathology in Alzheimer's disease. 133, 3699-3723 (2010). 423 9 Neff, R. A. et al. Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals 424 novel mechanisms and targets. 7 (2021). 425 10 Lam, B. et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease 426 syndrome. 5, 1-14 (2013). 427 Annese, A. et al. Whole transcriptome profiling of Late-Onset Alzheimer's Disease patients 11 428 provides insights into the molecular changes involved in the disease. 8, 4282 (2018). 429 12 Van Rooij, J. G. et al. Hippocampal transcriptome profiling combined with protein-protein 430 interaction analysis elucidates Alzheimer's disease pathways and genes. 74, 225-233 (2019). 431 13 Augustine, J. R. J. B. r. r. Circuitry and functional aspects of the insular lobe in primates including 432 humans. 22, 229-244 (1996). 433 Showers, M. J. C. & Lauer, E. W. J. J. o. C. N. Somatovisceral motor patterns in the insula. 117, 14
- 434 107-115 (1961).
  435 15 Kurth, F. *et al.* A link between the systems: functional differentiation and integration within the human insula revealed by meta-analysis. **214**, 519-534 (2010).
- 437 16 Molnar-Szakacs, I., Uddin, L. Q. J. N. & Reviews, B. Anterior insula as a gatekeeper of executive 438 control. **139**, 104736 (2022).
- 439 17 Gogolla, N. J. C. B. The insular cortex. **27**, R580-R586 (2017).
- 44018Dai, Z. *et al.* Identifying and mapping connectivity patterns of brain network hubs in Alzheimer's441disease. **25**, 3723-3742 (2015).
- 44219Fathy, Y. Y. *et al.* Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a443systematic review and meta-analysis.14, 2799-2816 (2020).
- 44420Jones, S. A. *et al.* Altered frontal and insular functional connectivity as pivotal mechanisms for445apathy in Alzheimer's disease. **119**, 100-110 (2019).
- Liu, X. *et al.* Altered functional connectivity of insular subregions in Alzheimer's disease. **10**, 107
  (2018).
- 44822Gazestani, V. *et al.* Early Alzheimer's disease pathology in human cortex involves transient cell449states. **186**, 4438-4453. e4423 (2023).

450 23 Mathys, H. et al. Single-cell atlas reveals correlates of high cognitive function, dementia, and 451 resilience to Alzheimer's disease pathology. 186, 4365-4385. e4327 (2023). 452 24 McCoy Jr, T. H. et al. High throughput phenotyping for dimensional psychopathology in electronic 453 health records. 83, 997-1004 (2018). 454 25 Insel, T. et al. Vol. 167 748-751 (Am Psychiatric Assoc, 2010). 455 26 Cuthbert, B. N. J. W. p. The RDoC framework: facilitating transition from ICD/DSM to dimensional 456 approaches that integrate neuroscience and psychopathology. 13, 28-35 (2014). 457 27 Carcone, D. & Ruocco, A. C. J. F. i. c. n. Six years of research on the national institute of mental 458 health's research domain criteria (RDoC) initiative: a systematic review. 11, 46 (2017). 459 28 Braak, H. & Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol* 460 Aging 16, 271-278; discussion 278-284, doi:10.1016/0197-4580(95)00021-6 (1995). 461 29 Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21, 462 doi:10.1093/bioinformatics/bts635 (2013). 463 30 Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008, 464 doi:10.1093/gigascience/giab008 (2021). 465 31 Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-466 aware quantification of transcript expression. Nature Methods 14, 417-419, 467 doi:10.1038/nmeth.4197 (2017). 468 Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level 32 469 estimates improve gene-level inferences. F1000Res 4, 1521, doi:10.12688/f1000research.7563.2 470 (2015). 471 33 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-472 seq data with DESeq2. Genome Biology 15, 550, doi:10.1186/s13059-014-0550-8 (2014). 473 34 Vogelgsang, J. S. et al. Dimensional clinical phenotyping using post-mortem brain donor medical 474 records: Association with neuropathology. 2023.2005. 2004.539430 (2023). 475 Fischer, D. S., Theis, F. J. & Yosef, N. Impulse model-based differential expression analysis of time 35 476 course sequencing data. Nucleic Acids Research 46, e119-e119, doi:10.1093/nar/gky675 (2018). 477 36 Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing 478 batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 479 882-883, doi:10.1093/bioinformatics/bts034 (2012). 480 37 Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level 481 datasets. Nature Communications 10, 1523, doi:10.1038/s41467-019-09234-6 (2019). 482 38 Vogelgsang, J. et al. Dimensional clinical phenotyping using post-mortem brain donor medical 483 records: post-mortem RDoC profiling is associated with Alzheimer's disease neuropathology. 484 Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 15, e12464, 485 doi:https://doi.org/10.1002/dad2.12464 (2023). 486 39 Mufson, E. J. et al. Braak stage and trajectory of cognitive decline in noncognitively impaired 487 elders. Neurobiology of Aging 43, 101-110, 488 doi:https://doi.org/10.1016/j.neurobiolaging.2016.03.003 (2016). 489 40 Nelson, P. T., Braak, H. & Markesbery, W. R. Neuropathology and cognitive impairment in 490 Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14, 491 doi:10.1097/NEN.0b013e3181919a48 (2009). 492 Schüller, M., Jenne, D. E. & Voltz, R. J. J. o. N. The human PNMA family: Novel neuronal proteins 41 493 implicated in paraneoplastic neurological disease. 169, 172-176 (2005). 494 42 Pang, S. W., Lahiri, C., Poh, C. L. & Tan, K. O. J. C. s. PNMA family: Protein interaction network and 495 cell signalling pathways implicated in cancer and apoptosis. 45, 54-62 (2018). 496 43 Xiong, J. et al. FSH blockade improves cognition in mice with Alzheimer's disease. Nature 603, 497 470-476, doi:10.1038/s41586-022-04463-0 (2022).

498	44	Fisher, D. W., Bennett, D. A. & Dong, H. J. N. o. a. Sexual dimorphism in predisposition to
499		Alzheimer's disease. 70, 308-324 (2018).
500	45	Heneka, M. T. et al. Neuroinflammation in Alzheimer's disease. 14, 388-405 (2015).
501	46	Eteleeb, A. M. et al. Brain high-throughput multi-omics data reveal molecular heterogeneity in
502		Alzheimer's disease. PLoS Biol 22, e3002607, doi:10.1371/journal.pbio.3002607 (2024).
503	47	Saura, C. A., Deprada, A., Capilla-López, M. D. & Parra-Damas, A. Revealing cell vulnerability in
504		Alzheimer's disease by single-cell transcriptomics. Seminars in Cell & Developmental Biology 139,
505		73-83, doi: <u>https://doi.org/10.1016/j.semcdb.2022.05.007</u> (2023).
506	48	Ross, C. A. & Margolis, R. L. Research Domain Criteria: Strengths, Weaknesses, and Potential
507		Alternatives for Future Psychiatric Research. Mol Neuropsychiatry 5, 218-236,
508		doi:10.1159/000501797 (2019).
509	49	Dalgleish, T., Black, M., Johnston, D. & Bevan, A. Transdiagnostic approaches to mental health
510		problems: Current status and future directions. J Consult Clin Psychol 88, 179-195,
511		doi:10.1037/ccp0000482 (2020).
512	50	Hengartner, M. P. & Lehmann, S. N. Why Psychiatric Research Must Abandon Traditional
513		Diagnostic Classification and Adopt a Fully Dimensional Scope: Two Solutions to a Persistent
514		Problem. <i>Front Psychiatry</i> <b>8</b> , 101, doi:10.3389/fpsyt.2017.00101 (2017).
515	51	Fisher, D. W. et al. Unique transcriptional signatures correlate with behavioral and psychological
516		symptom domains in Alzheimer's disease. Translational Psychiatry 14, 178, doi:10.1038/s41398-
517		024-02878-z (2024).
518	52	Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J. & Tsai, LH. J. T. J. o. N. Amyloid-
519		Independent Mechanisms in Alzheimer's Disease Pathogenesis. <b>30</b> , 14946 - 14954 (2010).
520	53	Dileep, V. et al. Neuronal DNA double-strand breaks lead to genome structural variations and 3D
521		genome disruption in neurodegeneration. 186, 4404-4421.e4420 (2023).
522	54	Ferreira, A. C. <i>et al</i> . From the periphery to the brain: Lipocalin-2, a friend or foe? <b>131</b> , 120-136
523		(2015).
524	55	Dekens, D. W. et al. Lipocalin 2 as a link between ageing, risk factor conditions and age-related
525		brain diseases. <b>70</b> , 101414 (2021).
526	56	Velasco, G. et al. Cloning and characterization of human MMP-23, a new matrix
527		metalloproteinase predominantly expressed in reproductive tissues and lacking conserved
528		domains in other family members. 274, 4570-4576 (1999).
529	57	Wang, X. et al. Distinct roles of telomerase activity in age-related chronic diseases: An update
530		literature review. 167, 115553 (2023).
531	58	Chen, WD. et al. The circadian rhythm controls telomeres and telomerase activity. 451, 408-414
532		(2014).
533	59	Lyon, M. S. & Milligan, C. J. N. L. Extracellular heat shock proteins in neurodegenerative diseases:
534		new perspectives. 711, 134462 (2019).
535	60	Foale, S., Berry, M., Logan, A., Fulton, D. & Ahmed, Z. J. N. r. r. LINGO-1 and AMIGO3, potential
536		therapeutic targets for neurological and dysmyelinating disorders? <b>12</b> , 1247 (2017).
537	61	Sun, X. & Lin, Y. J. T. i. n. Npas4: linking neuronal activity to memory. <b>39</b> , 264-275 (2016).
538	62	Lambert, JC. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for
539		Alzheimer's disease. <b>45</b> , 1452-1458 (2013).
540	63	Currais, A., Hortobágyi, T. & Soriano, S. J. A. The neuronal cell cycle as a mechanism of
541		pathogenesis in Alzheimer's disease. 1, 363 (2009).
542	64	Valkanova, V., Ebmeier, K. P. & Allan, C. L. J. J. o. a. d. CRP, IL-6 and depression: a systematic
543		review and meta-analysis of longitudinal studies. 150, 736-744 (2013).
544	65	Ishida, N. et al. SGLT1 participates in the development of vascular cognitive impairment in a
545		mouse model of small vessel disease. 727, 134929 (2020).

- 546 66 Jiang, Y. *et al.* An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4
  547 in female patients with Alzheimer's disease. 2, 616-634 (2022).
- 548 67 Soilu-Hänninen, M. *et al.* Expression of LIF and LIF receptor beta in Alzheimer's and Parkinson's 549 diseases. **121**, 44-50 (2010).
- Bian, Z. *et al.* Accelerated accumulation of fibrinogen peptide chains with Aβ deposition in
  Alzheimer's disease (AD) mice and human AD brains. **1767**, 147569 (2021).
- 552 69 Michlmayr, D., McKimmie, C. S. J. I. j. o. i., cytokine & research, m. Role of CXCL10 in central 553 nervous system inflammation. 1-18 (2014).
- 554 70 Sheng, Y. *et al.* MUC1 and MUC13 differentially regulate epithelial inflammation in response to inflammatory and infectious stimuli. **6**, 557-568 (2013).
- 556 71 Zhao, J. & Lang, M. J. C. D. D. New insight into protein glycosylation in the development of
  557 Alzheimer's disease. 9, 314 (2023).
- 55872Komander, D., Clague, M. J. & Urbé, S. J. N. r. M. c. b. Breaking the chains: structure and function559of the deubiquitinases. **10**, 550-563 (2009).
- 56073Ross, J. M., Olson, L. & Coppotelli, G. J. I. j. o. m. s. Mitochondrial and ubiquitin proteasome561system dysfunction in ageing and disease: two sides of the same coin?16, 19458-19476 (2015).
- F4 Hanpude, P., Bhattacharya, S., Dey, A. K. & Maiti, T. K. J. I. I. Deubiquitinating enzymes in cellular
  signaling and disease regulation. 67, 544-555 (2015).
- Harrigan, J. A., Jacq, X., Martin, N. M. & Jackson, S. P. J. N. r. D. d. Deubiquitylating enzymes and
  drug discovery: emerging opportunities. **17**, 57-78 (2018).
- 566 76 Niikura, T. J. B. e. B. A.-G. S. Humanin and Alzheimer's disease: The beginning of a new field.
  567 **1866**, 130024 (2022).
- 568
- 569
- 570
- 571
- 572
- 573
- 574
- 575
- 576
- 577
- 578
- 579
- 580
- 581
- 582
- 583
- 202
- 584

## 585 Figure Legends

586

#### 587 Figure 1. Transcriptional signature of dimensional RDoC cognition profiling.

- 588 (A) Heatmap showing gene expression signatures of all DEGs (p<sub>nominal</sub><0.05) with a significant up- or
- 589 down-regulated pattern over increasing RDoC cognition values in the dACG. The top ten up- or down-
- 590 regulated DEGs (all p<sub>FDR</sub><0.05) are labeled. Bar colors on the left side indicate whether genes are
- 591 clustered in an increasing (red) or decreasing (blue) trajectory. (B) Heatmap showing gene expression of
- 592 DEGs (p<sub>nominal</sub><0.05) with a significant up- or down-regulated pattern over increasing RDoC cognition
- values in the aINS. Top ten up- or down-regulated monotonous DEGs (all p<sub>FDR</sub><0.05) are labeled.
- 594

## 595 Figure 2. Identification of gene expression programs as a function of distinct RDoC cldomains

596 (A) Heatmaps showing expression trajectories of up- or down-regulated DEGs (p<sub>nominal</sub><0.05) over 597 increasing RDoC domain values separated for arousal, negative, positive and social in the dACG. Top ten 598 up- or down-regulated DE genes (all p<sub>FDR</sub><0.05) labeled. (B) Heatmaps showing analogous expression 599 pattern in the aINS, separated for arousal, negative, positive and social. (C) Upset plots showing the 600 overlap of DEGs of each RDoC domain, for increasing (left) and decreasing (right) genes, in the aINS. 601 Overlapping DEGs are indicated by intersecting lines among different domains. (D) Upset plots showing 602 overlapping DEGs for each RDoC domain, for increasing (left) and decreasing (right) genes, in the dACG. 603 (E) Heatmap showing overlapping and distinct regulatory pathways for each RDoC domain in aINS and 604 dACG (F). Colors indicate whether pathways are up- (red) or down-regulated (blue), and color depths 605 represent significance levels of the enriched pathways.

606

## 607 Supplemental Figure Legends

608

## 609 Figure S1. Identification of covariates in GLM differential expression model

(A-D) Principal component analysis of group, brain region, sex, and sequence batch. Colors indicate
sample subgroups under different conditions. (E) Pearson correlation matrix between the first five PCs
from principal component analysis, potential variables of interest, and the first two surrogate variables
from surrogate variable analysis. Colors indicate positive (red) and negative (blue) correlations. Dot size
in the upper-right panel and numbers in the lower-left panel indicate the significant correlation
coefficients.

616





Negative Arousal

Positive 5003